# v4.26\n\n## Related releases\n\n## Data changes\n

### Gene

```
AKT1S1 Summary Updated
ALOX5 Summary Updated
ALOX5 Background Updated
APEX1 Background Updated
APEX1 Summary Updated
CBLB Background Updated
CBLB Summary Updated
DHX15 Background Updated
DHX15 Summary Updated
POLH Background Updated
POLH Summary Updated
RPS6KB1 Background Updated
RPS6KB1 Summary Updated
TACSTD2 Background Updated
TACSTD2 Summary Updated
WEE1 Background Updated
WEE1 Summary Updated
```

### Alteration

```
APEX1 Amplification, Mutation Effect, Description Updated
APEX1 Amplification, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
APEX1 Amplification, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
APEX1 Amplification Added
CBLB Deletion, Mutation Effect, Description Updated
CBLB Deletion, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
CBLB Deletion, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
CBLB Deletion Added
CBLB Truncating Mutations, Mutation Effect, Description Updated
CBLB Truncating Mutations, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
CBLB Truncating Mutations, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
CBLB Truncating Mutations Added
CDKN1B P133T, Mutation Effect, Description Updated
CDKN1B P117S, Mutation Effect, Description Updated
CDKN1B P117S, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
CDKN1B P117S, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
CDKN1B P117S Added
CDKN1B Q163*, Mutation Effect, Description Updated
CDKN1B Q163*, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
CDKN1B Q163*, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
CDKN1B Q163* Added
CDKN1B E171*, Mutation Effect, Description Updated
CDKN1B E171*, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
CDKN1B E171*, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
CDKN1B E171* Added
ERBB2 R683Q, Mutation Effect, Description Updated
ERBB2 R683Q, Mutation Effect, Effect Updated
	 New: Inconclusive
	 Old: Likely Gain-of-function
ERBB2 R683Q, Mutation Effect, Oncogenic Updated
	 New: Inconclusive
	 Old: Likely
```

### Evidence

```
ALOX5 Gene Type, Oncogene Updated
ALOX5 Gene Type, Tumor Suppressor Updated
APEX1 Gene Type, Oncogene Updated
BRAF V600E, Colorectal Cancer, Summary Updated
BRAF V600E, Colorectal Cancer, Encorafenib + Cetuximab, Description Updated
BRAF V600E, Colorectal Cancer, Encorafenib + Cetuximab + FOLFOX Regimen, Description Updated
BRAF V600E, Colorectal Cancer, Encorafenib + Cetuximab + FOLFOX Regimen, FDA Level Updated
	 New: Fda2
	 Old: no
BRAF V600E, Colorectal Cancer, Encorafenib + Cetuximab + FOLFOX Regimen, Level Updated
	 New: 1
	 Old:
BRAF V600E, Colorectal Cancer, Encorafenib + Cetuximab + FOLFOX Regimen, Propagation to Other Liquid Tumor Types Updated
BRAF V600E, Colorectal Cancer, Encorafenib + Cetuximab + FOLFOX Regimen, Propagation to Other Solid Tumor Types Updated
BRAF V600E, Colorectal Cancer, Encorafenib + Cetuximab + FOLFOX Regimen 1 Added
CBLB Gene Type, Tumor Suppressor Updated
DHX15 Gene Type, Oncogene Updated
DHX15 Gene Type, Tumor Suppressor Updated
FGFR1 Fusions, Pancreatic Cancer, Summary Updated
FGFR1 Fusions, Pancreatic Cancer, Erdafitinib, Description Updated
FGFR1 Fusions, Pancreatic Cancer, Erdafitinib, FDA Level Updated
	 New: Fda2
	 Old: no
FGFR1 Fusions, Pancreatic Cancer, Erdafitinib, Level Updated
	 New: 2
	 Old:
FGFR1 Fusions, Pancreatic Cancer, Erdafitinib, Propagation to Other Liquid Tumor Types Updated
FGFR1 Fusions, Pancreatic Cancer, Erdafitinib, Propagation to Other Solid Tumor Types Updated
FGFR2 Oncogenic Mutations, Cholangiocarcinoma, Lirafugratinib, Description Updated
FGFR2 Fusions, Pancreatic Cancer, Erdafitinib, Description Updated
FGFR2 Fusions, Pancreatic Cancer, Summary Updated
FGFR2 Fusions, Pancreatic Cancer, Erdafitinib, FDA Level Updated
	 New: Fda2
	 Old: no
FGFR2 Fusions, Pancreatic Cancer, Erdafitinib, Level Updated
	 New: 2
	 Old:
FGFR2 Fusions, Pancreatic Cancer, Erdafitinib, Propagation to Other Liquid Tumor Types Updated
FGFR2 Fusions, Pancreatic Cancer, Erdafitinib, Propagation to Other Solid Tumor Types Updated
FGFR2 Fusions, Non-Small Cell Lung Cancer, Summary Updated
FGFR2 Fusions, Non-Small Cell Lung Cancer Added
FGFR2 Oncogenic Mutations, Non-Small Cell Lung Cancer, Summary Updated
FGFR2 Oncogenic Mutations, Non-Small Cell Lung Cancer, Erdafitinib, Description Updated
FGFR2 Oncogenic Mutations, Non-Small Cell Lung Cancer, Erdafitinib, FDA Level Updated
	 New: Fda2
	 Old: no
FGFR2 Oncogenic Mutations, Non-Small Cell Lung Cancer, Erdafitinib, Level Updated
	 New: 2
	 Old:
FGFR2 Oncogenic Mutations, Non-Small Cell Lung Cancer, Erdafitinib, Propagation to Other Liquid Tumor Types Updated
FGFR2 Oncogenic Mutations, Non-Small Cell Lung Cancer, Erdafitinib, Propagation to Other Solid Tumor Types Updated
FGFR2 Fusions, Cholangiocarcinoma, Lirafugratinib 3A Deleted
FGFR3 Fusions, Non-Small Cell Lung Cancer, Summary Updated
FGFR3 Fusions, Non-Small Cell Lung Cancer Added
FGFR3 Oncogenic Mutations, Non-Small Cell Lung Cancer, Summary Updated
FGFR3 Oncogenic Mutations, Non-Small Cell Lung Cancer, Erdafitinib, Description Updated
FGFR3 Oncogenic Mutations, Non-Small Cell Lung Cancer, Erdafitinib, FDA Level Updated
	 New: Fda2
	 Old: no
FGFR3 Oncogenic Mutations, Non-Small Cell Lung Cancer, Erdafitinib, Level Updated
	 New: 2
	 Old:
FGFR3 Oncogenic Mutations, Non-Small Cell Lung Cancer, Erdafitinib, Propagation to Other Liquid Tumor Types Updated
FGFR3 Oncogenic Mutations, Non-Small Cell Lung Cancer, Erdafitinib, Propagation to Other Solid Tumor Types Updated
FGFR3 FGFR3-TACC3 Fusion, FGFR3-BAIAP2L1 Fusion, Non-Small Cell Lung Cancer, Summary Updated
FGFR3 FGFR3-TACC3 Fusion, FGFR3-BAIAP2L1 Fusion, Non-Small Cell Lung Cancer Added
POLH Gene Type, Tumor Suppressor Updated
RPS6KB1 Gene Type, Oncogene Updated
TACSTD2 Gene Type, Oncogene Updated
WEE1 Gene Type, Tumor Suppressor Updated
```
